NDAORALTABLET
Approved
Nov 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZANAFLEX (tizanidine hydrochloride) by Enterprise Therapeutics is alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Approved for spasticity in adults. First approved in 1996.
Drug data last refreshed 19h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANAFLEX (tizanidine hydrochloride) is an oral alpha-2-adrenergic receptor agonist approved in 1996 for reducing spasticity in adults. It works by increasing presynaptic inhibition of motor neurons, with greatest effects on polysynaptic pathways to reduce facilitation of spinal motor neurons.
$0.5MPart D
LOE ApproachingProduct is nearing loss of exclusivity with minimal recent spending signals, suggesting team size and investment are likely contracting or transitioning to generic stewardship models.
Mechanism of Action
alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
Indications (1)
Clinical Trials (1)
BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity
Started Dec 2003
135 enrolled
Upper Limb Spasticity
Career Relevance
Working on ZANAFLEX offers limited growth potential given its LOE-approaching status and minimal linked job openings; career value lies in mature-product stewardship, generic defense strategy, and cost optimization rather than launch or expansion activities. This role is best suited for professionals seeking experience in late-lifecycle commercial management or transition planning in a competitive, commoditized market.
Worked on ZANAFLEX at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.